Cargando…

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review

Background: The long-term use of anti-TNF-α agents can lead to adverse effects, such as infections and immune-mediated cutaneous reactions. Whether de-escalation by dose reduction or interval lengthening reduces these adverse effects is uncertain. This systematic review aims to compare the incidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouhuys, Marleen, Lexmond, Willem S., van Rheenen, Patrick F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139158/ https://www.ncbi.nlm.nih.gov/pubmed/35625771 http://dx.doi.org/10.3390/biomedicines10051034

Ejemplares similares

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial
por: Bouhuys, Marleen, et al.
Publicado: (2021)

Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
por: van Rheenen, Hanna, et al.
Publicado: (2020)

Case Report: Systemic Small-Vessel Vasculitis in an Adolescent With Active Ulcerative Colitis
por: Bouhuys, Marleen, et al.
Publicado: (2021)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

The Effect of Anti-Tumor Necrosis Factor-Alpha Therapy within 12 Weeks Prior to Surgery on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
por: Cira, Kamacay, et al.
Publicado: (2022)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Systemic use of tumor necrosis factor alpha as an anticancer agent
por: Roberts, Nicholas J., et al.
Publicado: (2011)

The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients
por: Yazısız, Veli, et al.
Publicado: (2021)

Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis
por: Zhang, Qingfeng, et al.
Publicado: (2022)

Alopecia secondary to anti-tumor necrosis factor-alpha therapy()
por: Ribeiro, Lara Beatriz Prata, et al.
Publicado: (2015)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Effect of Probiotic Dose Escalation on Gut Microbiota and Clinical Outcomes in Preterm Infants—A Systematic Review
por: Rath, Chandra, et al.
Publicado: (2023)

Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
por: Hu, Yunwei, et al.
Publicado: (2020)

Two Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors
por: Masukawa, Ena, et al.
Publicado: (2021)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Acute esophageal necrosis: A systematic review and pooled analysis
por: Schizas, Dimitrios, et al.
Publicado: (2020)

Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis
por: Sutanto, Andryanto, et al.
Publicado: (2021)

Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods
por: Krack, Gundula, et al.
Publicado: (2016)

Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
por: Pascual-Camps, Isabel, et al.
Publicado: (2014)

Paradoxical Side Effect Related With Anti-Tumor Necrosis Factor Alpha Treatment
por: Aşkın, Ayhan, et al.
Publicado: (2017)

Human factors in escalating acute ward care: a qualitative evidence synthesis
por: Ede, Jody, et al.
Publicado: (2021)

Femoral head avascular necrosis in COVID-19 survivors: a systematic review
por: Hassan, Ahmed Abdelazim A., et al.
Publicado: (2023)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Iatrogenic Kaposi Sarcoma Precipitated by Anti-Tumor Necrosis Factor-Alpha (Anti-TNF-α) Therapy
por: Mariappan, Aathi Lakshmi, et al.
Publicado: (2021)

Alpha-Phellandrene and Alpha-Phellandrene-Rich Essential Oils: A Systematic Review of Biological Activities, Pharmaceutical and Food Applications
por: Radice, Matteo, et al.
Publicado: (2022)

Induced myelopathy after long-term anti-tumor necrosis factor alpha treatment
por: Modesto, C, et al.
Publicado: (2011)

Anti-Tumor Necrosis Factor Alpha for Retinal Diseases: Current Knowledge and Future Concepts
por: Mirshahi, Alireza, et al.
Publicado: (2012)

Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn’s Disease
por: Thurlapati, Aswani, et al.
Publicado: (2021)

Tumor Necrosis Factor Alpha Signaling and Organogenesis
por: You, Kai, et al.
Publicado: (2021)

The reduction of CSF tumor necrosis factor alpha levels in schizophrenia: no correlations with psychopathology and coincident metabolic characteristics
por: Zhu, Haibing, et al.
Publicado: (2016)

Operative Management of Avascular Necrosis of the Femoral Head in Skeletally Immature Patients: A Systematic Review
por: Migliorini, Filippo, et al.
Publicado: (2022)

Anti-tumor necrosis factor agents and COVID-19: A word of caution
por: Hajjar, Roy, et al.
Publicado: (2020)

Correction: Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia
por: Levin, Robert D, et al.
Publicado: (2010)

Adverse reactions of dimethyl sulfoxide in humans: a systematic review
por: Kollerup Madsen, Bennedikte, et al.
Publicado: (2019)

Cardiac Adverse Events after Vaccination—A Systematic Review
por: Parmar, Kanak, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis
por: Truong, Steven L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oasf19q63bdra3oggqc8gcqfnv